PDCD1 and hepatocellular carcinoma: In addition to PD-1 inhibition, miR-138 modulates the expression of other oncogenic drivers in HCC, such as cyclin D3 [99], SOX9 [100], and SIRT1 [101], confirming its dual function in oncogenic and immunoediting processes.